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CRISPR: REDEFINING GMOS—ONE EDIT AT A TIME  
Eric E. Williams* 
I. INTRODUCTION 
Genetically modified organisms (GMOs) are the center of some of the 
most polarizing beliefs in today’s society. Certain individuals view GMOs 
as long-sought solutions to some of the world’s biggest problems, from re-
cycling materials to fueling transportation to feeding the growing human 
population. Other groups, however, believe that GMOs are a threat to the 
natural world. These groups offer warnings, including the uncertainties re-
sulting from processing and modifying natural products, as well as the inde-
terminate long-term effects of making such changes. Although divergent in 
beliefs, both groups passionately argue their views online, in government 
forums, and in the scientific press. 
Herbert Boyer and Stanley Cohen are credited with the formulation of 
the first GMO – bacteria that was genetically modified to include a gene 
from another bacterium.1 In 1973, Boyer and Cohen inserted a particular 
gene from a bacterium into a plasmid.2 They then induced uptake of the 
plasmid by a different bacterium.3 The result was a modified bacterium with 
a novel gene that provided resistance to the antibiotic kanamycin, a property 
conferred by the gene from the original bacterium.4 
From these humble beginnings, the biotechnology community formed 
around GMOs has grown by leaps and bounds. The science behind GMOs 
has evolved at a breakneck pace, thanks to advances made by recombinant 
bacteria, by Polymerase Chain Reaction (PCR), and by transgenic plants. 
However, perhaps the biggest scientific discovery of an entire generation, 
CRISPR, offers the unique opportunity to rewrite the definition of GMOs as 
they are known today.    
CRISPR, an acronym for Clustered Regularly Interspaced Short Palin-
dromic Repeats, is a novel gene editing technology that has been called one 
 
* Eric E. Williams, Pharm.D., J.D., is a Partner in the Intellectual Property Department of 
Barnes & Thornburg LLP and works in Indianapolis, Indiana. Thank you to my legal and 
scientific colleagues for their kind assistance on this topic. A very special thank you to Dr. 
Harrison Pittman for providing me the opportunity to contribute on this topic. 
 1. Genetics and Genomics Timeline, GENOME NEWS NETWORK, http://www.genome
newsnetwork.org/resources/timeline/1973_Boyer.php (last visited Mar. 5, 2017). 
 2. Id. 
 3. Id. 
 4. Id. 
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of the greatest scientific discoveries in the last century.5 The CRISPR sys-
tem, also known as the “CRISPR-Cas9” system, is a simple and inexpensive 
method to identify an “unhealthy” genetic sequence in an organism, cut the 
sequence out, and then replace the removed “unhealthy” sequence with a 
“healthy” version.6 This amazing process results in an organism with a cor-
rected genetic sequence that, importantly, is made up entirely of its own 
native genes.7 
The fact that the CRISPR system can use an organism’s own genetic 
library to correct damaged DNA results in a far different outcome than some 
methods that have been historically used to create GMOs.8 Using CRISPR 
in this capacity, the corrected genetic system is not a “hybrid” mishmash of 
DNA obtained from different organisms. Instead, the corrected DNA in a 
CRISPR-modified organism comes from the organism itself.9 In other 
words, although an organism does in fact undergo genetic editing using 
CRISPR, the resulting CRISPR-modified organism is indistinguishable from 
a normal organism in nature that is free of the ailment that was fixed by the 
CRISPR process.10 
In particular, the agricultural community is struggling to understand 
how the CRISPR system will affect current procedures, processes, and 
products. In this regard, Maywa Montenegro, a food systems researcher and 
a PhD candidate in Environmental Science, Policy and Management at the 
University of California, Berkeley, may have said it best: 
CRISPR is giving us a rare opportunity, then, to escape GMO definitions 
stuck in the 1980s and begin treating agriculture and food as the complex 
systems they are. It invites us to update biotech governance to include 
expertise from a wider public and range of sciences. We’ll need to con-
sult not just geneticists but also ecologists. Not just natural scientists but 
social scientists. Not just scientists, but farmers, consumers, seed pro-
ducers and workers across the food chain.11 
 
 5. See Antonio Regalado, Who Owns the Biggest Biotech Discovery of the Century?, 
MIT TECH. REV. (Dec. 4, 2014), https://www.technologyreview.com/s/532796/who-owns-
the-biggest-biotech-discovery-of-the-century/. 
 6. Id. 
 7. Id. 
 8. Id. 
 9. Id. 
 10. Institute for Basic Science, Genome-edited Plants, Without DNA: CRIPSR-Cas9 
RNP Technique in Plants Could Be the Key to Feeding the Planet, SCI. DAILY (Oct. 19, 
2015), https://www.sciencedaily.com/releases/2015/10/151019123744.htm. 
 11. Maywa Montenegro, CRISPR is Coming to Agriculture – with Big Implications for 
Food, Farmers, Consumers and Nature, ENSIA (Jan. 28, 2016), https://ensia.com/voices/
crispr-is-coming-to-agriculture-with-big-implications-for-food-farmers-consumers-and-
nature/. 
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In summary, CRISPR is a game changer for defining what is and what 
is not a genetically modified organism. Part II of this paper will explain the 
science of using the CRISPR system as a genetic editing tool.12 Part III will 
explore the current and potential applications of CRISPR in humans, ani-
mals, and plants.13 Part IV will summarize the important battle over the in-
ventorship of the CRISPR process that will ultimately determine the true 
owner of the technology.14 Finally, Part V of this article will examine the 
growing regulatory quandary faced by various countries on how to classify 
organisms modified by CRISPR.15 
II. DEFINING THE CRISPR SYSTEM AND ITS USE AS A GENETIC EDITING 
TOOL 
Modifying organisms via genetic manipulation has been the foundation 
of biotechnology research for several decades.16 For most organisms, deoxy-
ribonucleic acid (DNA) is the main genetic material and is made of nucleo-
tide bases adenosine (A), thymidine (T), cytidine (C), and guanosine (G).17 
Nearly all advances in biotechnology research and innovation are developed 
from this basic framework. 
In 1984, CRISPR was first identified during a study of the bacterial ge-
nome.18 CRISPR is represented by short DNA sequences followed by the 
same DNA sequence in reverse, also known as the “palindromic se-
quence.”19 This is followed by about thirty base pairs of DNA, known as 
“spacer” DNA, which then is followed by a repeat of the palindromic se-
quence.20 These DNA sequences represent a significant portion of the bacte-
rial genome and almost all archaea, a domain and kingdom of single-celled 
microorganisms.21 For many years, the scientific community assumed that 
these sequences were nothing more than “junk” DNA due to the frequency 
 
 12. See infra Part II. 
 13. See infra Part III. 
 14. See infra Part IV. 
 15. See infra Part V. 
 16. See, e.g., Asude Alpman Durmaz et al., Evolution of Genetic Techniques: Past, 
Present, and Beyond, BIOMED RES. INT’L 1, 1 (2014). 
 17. U.S. National Library of Medicine, What Is DNA?, GENETICS HOME REFERENCE, 
https://ghr.nlm.nih.gov/primer/basics/dn https://ghr.nlm.nih.gov/primer/basics/dna (last visit-
ed Dec. 19, 2017). 
 18. Michael J. Stern et al., Repetitive Extragenic Palindromic Sequences: A Major 
Component of the Bacterial Genome, 37 CELL 1015, 1015 (1984) (the conserved nucleotide 
sequence identified as the REP (repetitive extragenic palindromic) sequence in E. coli and S. 
typhimurium is now recognized as the first description of the machinery now known as 
CRISPR technology). 
 19. Elizabeth E. Pennisi, The CRISPR Craze, 341 SCI. 833, 834 (2013). 
 20. Stern et al., supra note 18, at 1015. 
 21. Id. 
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of seemingly unimportant repetition in the sequences.22 This assumption, 
however, fell by the wayside as more and more genomic information be-
came available to scientists in the 1990s and 2000s.23 
In 2005, researchers discovered that the spacer DNA sequences in the 
bacterial genome actually matched the DNA sequences known to be present 
in viruses.24 This breakthrough indicated that that the spacer DNA sequences 
may not be junk DNA after all and ultimately suggested a role in microbial 
immunity.25 Bacteria are commonly infected by viruses, so scientists hy-
pothesized that bacteria may actually integrate the viral DNA into their own 
DNA as a sort of defense mechanism to quickly identify and disable viruses 
upon infection.26 In other words, bacteria appeared to be able to take up in-
vading viral DNA and make it part of the bacteria’s own genetic code to 
form a sort of “catalog” of viral DNA. If a virus infects the bacteria in the 
future, the bacteria can reference the catalog of viral DNA and readily iden-
tify the virus as an invading, non-bacterial organism. 
Dr. Jennifer A. Doudna, a researcher at the University of California, 
Berkeley, discovered how bacteria utilize CRISPR spacer DNA (crDNA) as 
a defense mechanism.27 Bacteria use a single-sided section of crDNA (crR-
NA) as a guide mechanism, in tandem with an enzyme known as Cas9, to 
identify a virus that had invaded the bacteria.28 Cas9 is an enzyme that cuts 
the identified viral DNA at the end of the crRNA complementary sequence, 
thus inactivating the virus.29 This simple mechanism is very effective at 
identifying specific genetic sequences and quickly inactivating them to pre-
vent damage. Essentially, the Cas9 enzyme cuts the DNA like scissors, and 
CRISPR is the guide mechanism that tells Cas9 where to cut. 
After realizing the power of CRISPR as a defense system in organisms, 
scientists began working on how to adapt the process as a genetic editing 
tool.30 Dr. Doudna and her team modified the system to create a single guide 
RNA (sgRNA) that could include any RNA sequence to direct the Cas9 pro-
 
 22. Id. (due to the repetitive nature of REP sequences, it was assumed that DNA only 
reflected nonsense “junk” sequences in the genome). 
 23. See Carl Zimmer, Breakthrough DNA Editor Born of Bacteria, QUANTA MAG. (Feb. 
6, 2015), https://www.quantamagazine.org/20150206-CRISPR-dna-editor-bacteria. 
 24. Id. 
 25. Id. 
 26. Id. 
 27. See Dipali G. Sashital et al., Mechanism of Foreign DNA Selection in a Bacterial 
Adaptive Immune System, 46 MOLECULAR CELL 606, 606 (2012). 
 28. Jennifer A. Doudna & Emmanuelle Charpentier, The New Frontier of Genome Engi-
neering with CRISPR-Cas9, 346 SCIENCE 1258096-1, 1258096-2-1258096-3, 1258096-5 fig. 
4 (2014). 
 29. Id. at 1258096-2. 
 30. Id. at 1258096-1to -5. 
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tein to cut DNA at a specific point.31 The innovative aspect of the CRISPR-
Cas9 system is that it uses a RNA-based recognition of DNA instead of a 
protein-based recognition.32 The result is that the CRISPR-Cas9 system is 
more effective and simpler than having to produce an individual protein for 
every desired genetic cleavage, which had been the gold standard in the ge-
netic world.33 
Scientists developed several competing genetic-editing technologies 
before CRISPR, including meganucleases,34 zinc finger nucleases (ZFNs),35 
and transcription activator-like effector nucleases (TALENs).36 However, 
CRISPR is seen to be advantageous over the competing systems due to its 
accessibility, its inexpensive cost, and the ease with which it can be made 
and used. 
To utilize the CRISPR system, scientists first create a CRISPR “guide” 
molecule that matches a specific DNA sequence of interest.37 In this regard, 
CRISPR is used as a kind of GPS device to find its intended target on the 
DNA double helix where genetic editing is desired.38 Once it arrives at the 
precise position in the DNA, CRISPR cuts and splices the DNA with Cas9 
enzyme in order to remove the sequence from the genome.39 The CRISPR 
system then incorporates a corrected sequence into the genome provided by 
scientists to “fix” the cut DNA sequence. 
As discussed in Part III of this paper, the CRISPR-Cas9 process has 
been harnessed into a powerful system that can edit specific sites of DNA in 
virtually any organism.40 Genetic modifications using CRISPR can be used 
to activate, add, delete, or suppress genes.41 In this way, CRISPR acts as a 
sort of “cut and paste” mechanism for genetic content within targeted re-
gions of an organism’s genome. At this early stage of development, the pos-
sibilities for CRISPR appear to be nearly endless. 
 
 31. Martin Jinek et al., A Programmable Dual-RNA-Guided DNA Endonuclease in 
Adaptive Bacterial Immunity, 337 SCIENCE 816, 819–20 (2012). 
 32. Id. 
 33. Pennisi, supra note 19, at 835. 
 34. Maria Jasin & Rodney Rothstein, Repair of Strand Breaks by Homologous Recom-
bination, 5 COLD SPRING HARBOR PERSP. BIOLOGY 1, 5 (2013). 
 35. Mattew H. Porteus & David Baltimore, Chimeric Nucleases Stimulate Gene Target-
ing in Human Cells, 300 SCI. 763, 763 (2003). 
 36. Matthew J. Moscou & Adam J. Bogdanove, A Simple Cipher Governs DNA Recog-
nition by TAL Effectors, 326 SCIENCE 1501, 1501 (2009). 
 37. See Amy Maxmen, The Genesis Engine, WIRED (Aug. 2015) http://www.wired
.com/2015/07/crispr-dna-editing-2/. 
 38. Id. 
 39. Id. 
 40. See infra Part III. 
 41. S. Antony Ceasar et. al., Insert, Remove, or Replace: A Highly Advanced Genome 
Editing System Using CRISPR/Cas9, 1863 BBA MOLECULAR CELL RES. 2333 (2016). 
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III. APPLICATIONS OF CRISPR 
As with any newly developing technology, the advancement of the 
CRISPR system is still in its infancy. However, given the simplicity and the 
low cost of using CRISPR, researchers have already utilized CRISPR to 
create improved livestock and plants.42 Targeted gene therapies for humans 
and animals will also likely be forthcoming.43 The estimates of the economic 
impact of CRISPR are staggering for such a newly developed technology, 
with one estimate predicting a market of more than $5.54 billion by 2021.44 
This section will discuss a few of the recent CRISPR developments for hu-
mans, animals, and plants. 
A. Human Applications of CRISPR 
The current and potential applications of CRISPR to the human ge-
nome are amongst the most controversial. Many CRISPR supporters are 
keen to promote the potential of the system to cure genetic disorders.45 The 
majority of CRISPR supporters believe that the power of the CRISPR sys-
tem could potentially outpace the ability of policymakers to consider allow-
able applications and their related social implications.46 Most moderate sup-
porters argue that taking the time to evaluate the moral consequences of 
CRISPR will not necessarily be the death knell for the technology as a 
whole.47 The extremist CRISPR supporters believe that “slowing down re-
search has a massive human cost” and that CRISPR opponents should just 
“[g]et out of the way.” 48 
Of course, CRISPR opponents are also prevalent and some even argue 
for a complete and total ban of the technology.49 Commonly, these CRISPR 
 
 42. See Heidi Ledford, CRISPR, The Disruptor, NATURE (June 3, 2015), http://
www.nature.com/news/crispr-thedisruptor-1.17673. 
 43. Id. 
 44. See Genome Editing/Genome Engineering Market Worth 5.54 Billion USD by 2021, 
MARKETSANDMARKETS, http://www.marketsandmarkets.com/PressReleases/genome-editing-
engineering.asp (last visited Aug. 28, 2017). 
 45. See, e.g., Steven Pinker, Opinion, The Moral Imperative for Bioethics, BOS. GLOBE 
(Aug. 1, 2015), https://www.bostonglobe.com/opinion/2015/07/31/the-moral-imperative-for-
bioethics/JmEkoyzlTAu9oQV76JrK9N/story.html. 
 46. See Edward Lanphier et al., Don’t Edit the Human Germ Line, NATURE (Mar. 12, 
2015), https://www.nature.com/news/don-t-edit-the-human-germ-line-1.17111. 
 47. See id. at 411. 
 48. Pinker, supra note 45. 
 49. See Sarah Karlin, Gene Editing: The Next Frontier in America’s Abortion Wars, 
POLITICO (Feb. 16, 2016), https://www.politico.com/story/2016/02/gene-editing-abortion-
wars-219230. 
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opponents cite the potential for creation of “designer babies” and concern 
about the potential for grave social inequality.50 
Nevertheless, the science of CRISPR has marched on even in light of 
the controversies, and human CRISPR applications currently in develop-
ment are plentiful. Human diseases caused by genetic mutations are prime 
targets of CRISPR technology.51 Scientists from China using CRISPR on 
nonviable fertilized embryos have already edited the gene responsible for β-
thalassaemia, a potentially fatal blood disorder.52 Other researchers using 
CRISPR have been able to permanently inactivate the human immunodefi-
ciency virus (HIV) in human blood cells, representing a possible new ave-
nue for curing AIDS in the human population.53 Modification of the human 
genome could even potentially eradicate genetically inherited diseases like 
Down syndrome, cystic fibrosis, and Huntington’s disease, as well as certain 
genetically linked cancers.54 
In summary, the potential human applications of CRISPR are vast. In 
light of safety, morality, and regulatory concerns, only time will tell if these 
exciting applications will come to fruition. 
B. Animal Applications of CRISPR 
As CRISPR can be used to genetically edit virtually any germline cell, 
animals are also at the forefront of the technological applications. CRISPR 
has the potential to impact not only agriculturally important livestock ani-
mals, but also companion animals throughout the world. 
Of course, CRISPR modification of animals can also be targeted to im-
pact human health. For instance, researchers are exploring the possibility of 
altering the pig genome so that pigs could, in theory, grow human organs for 
transplant.55 CRISPR can also repair defective DNA in mice and cure them 
of genetic disorders, which in turn could influence the cure of related human 
disorders.56 
 
 50. See id. 
 51. Id. 
 52. Id. 
 53. See Rafal Kaminski et al., Elimination of HIV-1 Genomes from Human T-Lymphoid 
Cells by CRISPR/Cas9 Gene Editing, 6 SCI. REP. 1, 1–2 (Mar. 4, 2016), http://www.nature
.com/articles/srep22555. 
 54. See David Cyranoski & Sara Reardon, Chinese Scientists Genetically Modify Human 
Embryos: Rumors of Germline Modification Prove True -and Look to Reignite an Ethical 
Debate, NATURE (April 22, 2015), http://www.nature.com/news/chinese-scientistsgenetically-
modifyhuman-embryos-1.17378. 
 55. See Kristen V. Brown, Inside the Garage Labs of DIY Gene Hackers, Whose Hobby 
May Terrify You, FUSION (Mar. 29, 2016), http://projectearth.us/inside-the-garage-labs-of-
diy-gene-hackers-whose-hobby-1796423884. 
 56. See Zimmer, supra note 23. 
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Other animals can benefit from the CRISPR platform, for example by 
instituting disease resistance into the genome. To combat the depletion of 
honeybees around the world due to disease and parasites, researcher Brian 
Gillis is investigating the genomes of “hygienic” honeybees for potential 
CRISPR application.57 These hygienic bees are known to compulsively 
clean their hives in order to remove sick and infested bee larvae, and are 
shown to be less susceptible to mites, fungi, and other pathogens compared 
to other strains.58 Identification of honeybee genomics associated with this 
hygienic behavior may lead to genomic editing via CRISPR to improve hive 
heath and to stem the worldwide honeybee depletion. 
In addition, researchers at the University of Missouri have used 
CRISPR to modify cell surface proteins in pigs to make them virtually re-
sistant to the deadly swine disease porcine reproductive and respiratory syn-
drome (PRRS).59 According to estimates, PRRS costs producers in North 
America more than $600 million on an annual basis,60 and there is no cure.61 
However, using CRISPR, the pig genome was edited to disable the protein 
responsible for entry of the virus into swine cells, and the modification actu-
ally resulted in protection from the deadly disease.62 
CRISPR could also be used to make agriculture more humane. For ex-
ample, long horns on cattle can cause injuries, so farmers generally remove 
the horns via burning, cutting, or chemical techniques.63 Although polled 
cattle varieties exist, crossing these animals with more “elite” meat or dairy 
cattle breeds may reduce the quality of the resultant offspring.64 CRISPR 
gene editing has been used to eliminate horns from cattle by transferring the 
non-horn gene from one species into an “elite” breed.65 
 
 57. Sara Reardon, Welcome to the CRISPR Zoo, NATURE (Mar. 9, 2016), http://www.
nature.com/news/welcome-to-the-crispr-zoo-1.19537. 
 58. Id. 
 59. Monique Brouillette, You Can Edit a Pig, but it Will Still Be a Pig, SCI. AM. (Mar. 
2016) at A22, subsequently published as, Monique Brouillette, Scientists Breed Pigs Re-
sistant to a Devastating Infection Using CRIPSR, SCI. AM. (Mar. 1, 2016), https://www.
scientificamerican.com/article/scientists-breed-pigs-resistant-to-a-devastating-infection-
using-crispr/. 
 60. See Derald J. Holtkamp et al., Assessment of the Economic Impact of Porcine Re-
productive and Respiratory Syndrome Virus on United States Pork Producers, 21 J. OF SWINE 
HEALTH AND PROD. (2013). 
 61. See Porcine Reproductive and Respiratory Syndrome (PRRS), PIG SITE, 
http://www.thepigsite.com/pighealth/article/142/porcine-reproductive-and-respiratory-
syndrome-prrs/ (last visited Dec. 14, 2017). 
 62. Brouillette, supra note 59. 
 63. Reardon, supra note 57. 
 64. Id. 
 65. Wenfang Tan et al., Efficient Nonmeiotic Allele Introgression in Livestock Using 
Custom Endonucleases, 110 PROC. NAT’L. ACAD. SCI. U.S.16526–27 (2013). 
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Furthermore, CRISPR technology could result in a more fantastical ap-
plication – reviving species of extinct animals.66 Although talk of bringing 
back the wooly mammoth (Mammuthus primigenius) has existed for years, 
CRISPR may facilitate this undertaking by editing the genome of existing 
elephant species, such as the Indian elephant.67 Such an application will re-
quire several more years of research, but could result in a Jurassic Park-like 
plotline becoming reality. 
In summary, animal applications of CRISPR are far-reaching, but with-
in the purview of researchers around the globe. Generally, given lower regu-
latory thresholds and fewer social morality issues, applications resulting 
from CRISPR editing of animal germlines may be more plentiful and faster 
to market than their human counterparts. 
C. Plant Applications of CRISPR 
Applications of CRISPR to the plant world have also flourished.68 Pub-
lished research demonstrates that plant modification via CRISPR is more 
successful, and also more efficient, than previously developed genetic engi-
neering methods.69 Importantly, thanks to CRISPR, curing crop diseases and 
creating crops that are immune to disease may soon become the normal 
course for genetically modified plants.70 
The use of CRISPR for agriculturally important crops is of great signif-
icance given the rapidly growing global population. Although the global 
population has increased by approximately 60% over the past twenty years, 
grain production per capita has actually decreased worldwide.71 If popula-
tion growth rates continue according to the current pace, the world popula-
tion will double again within fifty years, and estimates show that food pro-
duction must also double by the year 2050 in order to keep up with de-
mands.72 Therefore, creating new ways to feed a growing population must 
be explored by any means necessary. 
Several success stories of using CRISPR to modify crops have already 
emerged. For example, Chinese researchers using CRISPR developed a 
strain of wheat that is resistant to powdery mildew, a destructive fungal 
 
 66. Reardon, supra note 57. 
 67. Id.; See also Zimmer, supra note 23. 
 68. Doudna & Charpentier, supra note 28, at 1258096-5. 
 69. Id. 
 70. See, e.g., Khaoula Belhaj et al., Plant Genome Editing Made Easy: Targeted Muta-
genesis in Model and Crop Plant Using The CRISPR/Cas System, PLANT METHODS, (Oct. 11, 
2013), at 1, https://plantmethods.biomedcentral.com/articles/10.1186/1746-4811-9-39. 
 71. Samir Suweis et al., Resilience and Reactivity of Global Food Security, 112 PROC. 
NAT’L. ACAD. SCI. U.S. 6902, 6902, 6905 (2015). 
 72. Id. at 6902. 
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pathogen.73 The Chinese researchers edited the wheat genome to delete cer-
tain genes that encode proteins that repress defenses against the mildew.74 
Thus, simple genetic editing via CRISPR can stop mildew in its tracks, ra-
ther than using heavy doses of fungicides to control the disease.75 The re-
sults are more effective and environmentally friendly compared to current 
methods. 
Researchers have also successfully created tomatoes with prolonged 
life via CRISPR by turning off the genes that control how quickly the toma-
toes ripen.76 Furthermore, using CRISPR methods, researchers are working 
on engineering vegetables that possess enhanced nutrition.77 Because vege-
tables can make their nutrients more available, such as lycopine and glucos-
inolates in broccoli, humans can benefit even more from eating their vegeta-
bles.78 
There appears to be a myriad of CRISPR applications in the plant 
world, and agricultural companies are already on board.79 For example, 
DuPont Pioneer has invested in Caribou Biosciences, the startup co-founded 
by CRISPR co-inventor Jennifer Doudna, which explores the use of genome 
editing on corn, soybeans, wheat, and rice.80 DuPont Pioneer has announced 
plans to begin selling seeds made with CRISPR technology within five 
years.81 
IV. INVENTORSHIP OF CRISPR 
The CRISPR system’s multitude of applications, both real and theoreti-
cal, is developing at a breakneck pace. But what was the first group to invest 
in CRISPR’s function for gene editing? And, perhaps more importantly, 
which group owns the intellectual property rights to use CRISPR for gene 
editing? The final answer is yet to be determined, but is currently playing 
out in the U.S. Patent Office and perhaps in the federal court system.82 
 
 73. David Talbot, Chinese Researchers Stop Wheat Disease with Gene Editing, MIT 
TECH. REV. (Jul. 21, 2014), https://www.technologyreview.com/s/529181/chinese-researchers
-stop-wheat-disease-with-gene-editing/. 
 74. Id. 
 75. Id. 
 76. See Michael Specter, The Gene Hackers, NEW YORKER (Nov. 16, 2015), http://
www.newyorker.com/magazine/2015/11/16/the-gene-hackers. 
 77. Jeannine Otto, More Nutritious and Tastier Vegetables? CRISPR Gene Editing 
Could Dramatically Boost Consumption, GENETIC LITERACY PROJECT (Feb. 16, 2017), 
https://www.geneticliteracyproject.org/2017/02/16/nutritious-tastier-vegetables-crispr-gene-
editing-dramatically-boost-consumption/. 
 78. Specter, supra note 76. 
 79. Talbot, supra note 73. 
 80. Id. 
 81. Specter, supra note 76. 
 82. Otto, supra note 77. 
2017] CRISPR GENE EDITING 447 
The story of who invented the use of CRISPR for gene editing focuses 
on two research groups.83 One research group was led by Dr. Jennifer Doud-
na at the University of California, Berkeley.84 Dr. Doudna and French re-
searcher, Emmanuelle Charpentier, were the first scientists to demonstrate 
that CRISPR could edit purified DNA, and published these findings in the 
journal Science in the summer of 2012.85 The second research group was led 
by the laboratory of Dr. Feng Zhang of The Broad Institute of MIT and Har-
vard.86 In early 2013, Dr. Zhang published research demonstrating that 
CRISPR could be used to modify human genes.87 
The history of the patent applications arising from both Dr. Doudna’s 
group and from Dr. Zhang’s group is more complicated.88 In March 2013, 
Dr. Doudna filed a patent application regarding the general CRISPR-Cas9 
system, which included a whopping 155 claims.89 In October 2013, Dr. 
Zhang filed a patent application and requested that the application be placed 
on the accelerated examination track by the United States Patent and 
Trademark Office (USPTO).90 
Because of Dr. Zhang’s request for his patent to be placed on the accel-
erated track, Dr. Zhang’s patent was first issued on April 15, 2014.91 Specif-
ically, the patent granted Dr. Zhang the right to exclude others from imple-
menting the commercial use of CRISPR technology for eukaryotic cells 
(e.g., cells of humans and other animals).92 As a result, Dr. Zhang was 
granted control over CRISPR applications for use in humans, monkeys, 
pigs, and mice, which represent the majority of test models that can be used 
for advancement of human disease therapeutics.93 In other words, with the 
grant of the patent, Dr. Zhang was given the keys to the vehicle that un-
doubtedly represents the possibility of generating the most profitable uses of 
CRISPR technology. 
 
 83. Specter, supra note 76. 
 84. Id. 
 85. Id. 
 86. Id. 
 87. Le Cong et al., Multiplex Genome Engineering Using CRISPR/Cas Systems, 339 
SCI. 819, 822 (2013); see also Specter, supra note 76. 
 88. See generally Jacob S. Sherkow, The CRISPR Patent Interference Showdown Is On: 
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As filed, the two patent applications can seemingly be distinguished.94 
Dr. Doudna’s patent application contained language that could be interpret-
ed to limit the claims to apply CRISPR only to prokaryotic cells.95 In con-
trast, Dr. Zhang’s application claimed a method of performing CRISPR edit-
ing in eukaryotic cells.96 In light of the patent grant to Dr. Zhang, Dr. Doud-
na’s group amended the claims of their patent application to remove the 
suggestion that the claims are limited to prokaryotic cells.97 This amendment 
provided Dr. Doudna the opportunity to request that the USPTO determine 
which competing party is truly entitled to a patent on CRISPR technology.98 
Clearly, Dr. Doudna’s patent application was filed first and thus was 
given an earlier priority date than Dr. Zhang’s patent application. As a re-
sult, Dr. Doudna petitioned the USPTO to institute an interference proceed-
ing in order to argue that Dr. Zhang’s already issued patent “interfere[ed]” 
with Dr. Doudna’s ability to obtain a patent on her earlier filed application.99 
The purpose of an interference proceeding is to determine which party was 
actually the first to invent a particular claimed technology.100 
On January 11, 2016, the USPTO granted Dr. Doudna’s request for an 
interference proceeding of the two patent filings, and a number of disputed 
claims between the two patent filings became at issue.101 The interference 
proceeding was thereafter argued before a panel of judges in order to deter-
mine who was the true inventor. Several motions and oral proceedings were 
undertaken before the USPTO issued its decision. 
During the interference proceeding, Dr. Zhang’s group argued that the 
two competing patent filings actually represented different claims—Zhang’s 
patent claiming CRISPR for use on eukaryotic cells, and Doudna’s patent 
claiming CRISPR for use on prokaryotic cells like bacteria.102 In contrast, 
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Dr. Doudna’s group argued that their patent filing dominated the later patent 
filing by Dr. Zhang because Dr. Doudna’s patent application covered all 
aspects of CRISPR, not just prokaryotes.103 In other words, Dr. Doudna as-
serted that her group was the rightful owner of the patent issued to Dr. 
Zhang because they, in fact, invented the technology first. 
In a decision rendered in February 2017, the USPTO upheld the patents 
issued to Dr. Zhang’s group, stating that the patents were valid because they 
were distinguishable from the patent filings of Dr. Doudna’s group.104 As a 
result, the USPTO found that the most lucrative applications of CRISPR 
technology, the editing of eukaryotic cells such as humans, animals, and 
plants, belong to Dr. Zhang and The Broad Institute.105 The decision was 
immediately reflected in the business world, as stock in Editas Medicine, a 
biotechnology company that licensed the CRISPR patents owned by The 
Broad Institute, surged following announcement of the USPTO verdict.106 
However, the battle over CRISPR patent rights is far from over. Dr. 
Doudna’s group could appeal the USPTO’s decision and further challenge 
the ownership of the patents. Alternatively, there is still the possibility for 
the two competing groups to reach a settlement agreement. Moreover, the 
patent rights outside the United States are still up for grabs and a patent bat-
tle may be forthcoming in other jurisdictions, such as Europe.107 
In the wake of the USPTO’s decision, both Dr. Doudna and Dr. Zhang 
were allowed to maintain ownership of their respective patents.108 However, 
the USPTO interim decision has created a cloud of uncertainty for entities 
that desire to use CRISPR gene editing in eukaryotic cells. For example, it is 
unclear if a license for using CRISPR on eukaryotic cells must be obtained 
from the University of California, Berkeley (the owner of the Doudna pa-
tents), The Broad Institute (the owner of the Zhang patents), or both.109 If 
researchers are compelled to obtain a license from both entities, the cost of 
commercializing CRISPR technology may ultimately increase.110 However, 
it does not appear that the ongoing patent rights battle has slowed down re-
search on utilizing CRISPR; in fact, many groups have developed new 
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methods that may be outside the scope of the claims of both the Doudna and 
Zhang patents.111 
In summary, The Broad Institute won an important early victory in the 
battle for ownership of CRISPR applications. However, the jury is still out 
on who will be the ultimate victor in the war. In the meantime, the science 
surrounding CRISPR continues to march on by exploring even more innova-
tive pathways. 
V. REGULATORY ASPECTS OF CRISPR-EDITED PRODUCTS 
As discussed previously, the phrase “genetically modified organism” 
evokes strong feelings and beliefs from both proponents and opponents of 
GMOs.112 However, the unique mechanism of the CRISPR system presents 
an opportunity to redefine how “gene edited” animals and plants are viewed 
by scientists, regulators, and consumers. Before exploring CRISPR’s varied 
regulatory aspects in human, animal, and plant organisms, it is informative 
to understand the scope of how “traditionally viewed” GMOs are regulated. 
A. Current Regulation of GMOs 
Generally, there are two processes by which GMOs are regulated by 
worldwide agencies. The first view is a product-focused approach that eval-
uates the final genetically modified product compared to the natural, unmod-
ified product.113 Alternatively, the second view is a process-focused ap-
proach that emphasizes review of the actual process by which the GMO is 
produced.114 The biotechnology industry prefers regulation that is product-
focused because the genetic modification process itself is not stigmatized 
during evaluation of a GMO. However, in the end, both product and process 
focused regulatory reviews consider the method that is used to produce the 
GMO, although method of production is considered less in the product-
focused review.115 
In the United States, there is no federal legislation specifically directed 
to review GMOs.116 Instead, GMOs are regulated by various existing gov-
ernment agencies that are set up to evaluate the health, safety, and environ-
mental impact of the products under the Coordinated Framework for Regu-
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lation of Biotechnology, published in 1986.117 According to this regulation, 
there are three tenets: “(1) U.S. policy would focus on the product of genetic 
modification (GM) techniques, not the process itself, (2) only regulation 
grounded in verifiable scientific risks would be tolerated, and (3) GM prod-
ucts are on a continuum with existing products and, therefore, existing stat-
utes are sufficient to review the products.”118 
The process of regulatory review and approval varies depending on the 
type of GMO.119 For example, “food, drug, and biological product GMOs 
are regulated under the Federal Food, Drug, and Cosmetic Act and the Pub-
lic Health Service Act . . . by the Food and Drug Administration (FDA).”120 
Plant GMOs are regulated according to the “Animal and Plant Health In-
spection Service by the U.S. Department of Agriculture (USDA) under the 
Plant Protection Act.”121 Pesticide and microorganism GMOs are regulated 
pursuant to the “Federal Insecticide, Fungicide and Rodenticide Act and the 
Toxic Substances Control Act by the Environmental Protection Agency 
(EPA).”122 
Compared to other countries, regulation on GMO development in the 
United States is relatively favorable.123 For the U.S., GMOs are very im-
portant to the biotechnology industry from an economic standpoint.124 For 
example, the U.S. leads the world in producing genetically modified 
crops.125 In 2012, there were 420.8 acres of biotech crops worldwide, and 
the U.S. accounted for over 40% of this production (171.7 acres).126 Fur-
thermore, the majority of several different types of crops grown in the U.S. 
are now comprised of genetically engineered varieties.127 For instance, in 
2013, 93% of the soybeans, 90% of the cotton, and 90% of the corn grown 
in the U.S. were genetically engineered crops, due to either herbicide toler-
ance or an insect resistance.128 
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On the other side of the spectrum, the regulation of GMOs in the Euro-
pean Union (EU) is vastly different. Regulatory laws passed in 2003 caused 
the EU to have possibly the most stringent GMO regulations in the world, 
which primarily utilize the process-based approach to regulatory review.129 
As of 2010, the EU considers all GMO crops to be “new foods.”130 As a 
result, each GMO crop is subjected to an extensive, scientific-based evalua-
tion by the European Food Safety Authority (EFSA) on a case-by-case ba-
sis.131 In turn, the EFSA agency reports to the European Commission (EC), 
which proceeds to draft proposals to either grant or refuse authorization of 
the GMO crop for submission to the “Section on GM Food and Feed of the 
Standing Committee on the Food Chain and Animal Health.”132 If accepted, 
the proposal is then either adopted by the European Commission or is 
passed on to the Council of Agricultural Ministers.133 Thereafter, the Coun-
cil has a three-month window to either vote for or against the proposal, and 
if a majority vote is not achieved, the proposal returns to the EC, which then 
adopts it.134 The extreme amount of regulatory review and oversight over 
GMO crops, divided between multiple agencies within the EU, can result in 
tremendous delays in garnering approval. 
The role of the EFSA is to use independent scientific research to advise 
the EU in order to protect not only consumers but also the environment.135 
This risk assessment includes evaluations to the molecular characterization 
of the GMO crop, its potential toxicity, and also its potential to impact the 
environment.136 Each GMO that is approved must be reassessed every 10 
years.137 Moreover, applicants desiring to cultivate or to process the GMOs 
must further deliver a detailed surveillance plan outlining the steps to be 
taken after GMO authorization.138 In other words, even after garnering an 
approval in the EU, the GMO crop is still subject to multiple layers of regu-
latory review. 
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B. Regulation of CRISPR Human Applications 
In the United States, the FDA has the responsibility to review all gene 
transfer therapy products and research for both safety and effectiveness.139 In 
this context, the term “gene-therapy products” refers to biologically based 
articles, such as articles that are removed from a human patient, modified 
outside the body, and then placed back into the human patient.140 Further-
more, “gene-therapy products” also include both natural and synthetic arti-
cles that are introduced to a human patient in order to genetically alter the 
patient’s cells.141 
Research protocols that are reviewable by the FDA comprise transmis-
sions of genetic material into a human patient for the purpose of replacing 
absent or defective DNA in an attempt to treat or cure a disease in the pa-
tient.142 Such a protocol is defined as a clinical trial, which would necessitate 
approval by the FDA.143 
However, even in light of the broad authority of the FDA to regulate 
gene-therapies and research protocols, the FDA’s regulation of the use of 
the CRISPR system to actually modify the human genome is uncertain.144 
As pure genetic material and embryos are not technically “human subjects,” 
the FDA technically does not have the authority to regulate products and 
research protocols related to human germline modification.145 In other 
words, scientists may perform experiments on human embryos and genetic 
material as long as the items are not “aimed at the development of a ‘prod-
uct’ subject to its approval.”146 
Once a CRISPR-edited organism begins to be developed as a product 
or is the subject of development requiring clinical trials, the regulatory re-
view of these activities would fall squarely within the FDA’s purview. Thus, 
gene therapies utilizing the CRISPR system with the intention of treating 
human patients are subject to the stringent review procedures that other 
drugs and biologics must currently follow in order to garner FDA approval. 
History has shown that as the FDA becomes more comfortable with a 
particular system of therapeutics, the path to approval is somewhat standard-
ized as later registered products can build off of the successes of previously 
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accepted products. However, as the early human applications of CRISPR 
editing are currently blazing new trails within the FDA, the agency will un-
doubtedly maintain a watchful eye on these therapies in the near future. 
C. Regulation of CRISPR Animal Applications 
Like human applications of CRISPR, the use of gene editing on ani-
mals intended for food would be governed in the United States by the 
FDA.147 This process appears to be relatively straightforward, given that the 
FDA currently regulates genetically engineered animals. 
On January 18, 2017, two days before President Obama left office, the 
FDA released three proposed regulations addressing different categories of 
products.148 In particular, one proposal was directed to regulation of “inten-
tionally altered” DNA in animals.149 According to this draft proposal, the 
review of all animals with an “intentionally altered” genome would be sub-
ject to evaluation for safety and efficacy in a manner similar to the review 
process for new drugs.150 
This proposed regulation was immediately met with criticism from 
CRISPR researchers. Given the accuracy and precision of the CRIPSR pro-
cess to edit an animal’s genome without the introduction of nonnative DNA, 
researchers were hopeful that these gene-editing products would be regulat-
ed less stringently than animals that are genetically engineered by introduc-
ing foreign DNA.151 Furthermore, the inclusion of an “‘intent”‘ element in 
the proposed regulation was also questioned.152 Because the U.S. has gener-
ally followed a product-based approach to regulating genetically-altered 
animals, many researchers were baffled as to why animals with an “inten-
tionally altered” genome would be subjected to increased scrutiny.153 “The 
trigger for their regulation is whether the animal was intended to be made, 
and what does intention have to do with risk,” commented Alison van 
Eenennaam, an animal geneticist at the University of California, Davis. 
“The risk has to do with the attributes of the product.”154 
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In particular, many people are concerned that, if implemented, the pro-
posed regulations would result in the development of CRISPR-edited ani-
mals to slow down or to be abandoned completely by researchers.155 In other 
words, the increased regulation of the animals via FDA review may cause 
businesses and universities to think twice before investing the time and ef-
fort to create improved animals via gene editing. Those who cannot remem-
ber the past are condemned to repeat it, and such companies undoubtedly 
recall the development of genetically engineered salmon by AquaBounty 
Technologies.156 
In 1995, AquaBounty began the approval process for the development 
of an Atlantic salmon (Salmo salar) engineered with genes from Chinook 
salmon (Oncorhynchus tshawytscha) in order to promote rapid growth of the 
genetically modified fish.157 However, the path to regulatory approval was 
lengthy and laborious. AquaBounty had to perform over 50 studies to 
demonstrate that the genetically modified salmon posed no unusual risks 
before the FDA finally approved the fish for sale in November 2015.158 In 
total, AquaBounty spent approximately $60 million on the development of 
the fish. Even after gaining approval, the FDA later determined that the 
salmon cannot be sold in the United States until a final determination is 
made on whether the fish must be labeled as genetically modified.159 
The FDA’s proposed regulation in January 2017 was a setback to sci-
entists currently engaged in the development of CRISPR-edited animals. For 
example, the gene editing company Recombinetics, located in St Paul, Min-
nesota, has developed hornless dairy cattle by using gene editing.160 The 
gene editing to create the polled animal inserts a gene from naturally horn-
less beef cattle into a breed of the same species used in milk production.161 
As discussed previously, this process could ease animal welfare concerns 
associated with the removal of horns via burning, cutting, or chemical tech-
niques.162 
In December 2016, Recombinetics informed the FDA that it intended 
to sell food from the genetically edited cattle without receiving FDA ap-
proval, which is allowable if the food label states that the product is “gener-
ally recognized as safe.”163 However, with the uncertainty surrounding the 
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newly proposed FDA regulation, this decision has been thrown into jeop-
ardy. 
It is important to note that the January 2017 documents published by 
the FDA are simply proposals, and full implementation of the proposed pro-
cedures will take time, if they happen at all. The draft regulations are subject 
to receive public comments until April 2017; based on feedback, the regula-
tory approach may be further modified by the FDA.164 Moreover, it is uncer-
tain how the new administration under President Trump will oversee the 
proposed regulations. In the end, the proposed regulations have been the 
subject of many discussions for the future of CRISPR’s animal editing, and 
it remains to be seen whether they represent a speed bump or a roadblock 
for future developments. 
D. Regulation of CRISPR Plant Applications 
In the U.S., plants with genetic modifications or genetic editing are 
regulated by the USDA.165 In contrast to human and animal applications of 
CRISPR, the regulatory pathway for CRISPR-edited plants has already been 
assessed, both in the United States and abroad. 
In April 2016, the USDA determined that a CRISPR-edited mushroom 
developed by scientists at Penn State University did not have to undergo 
regulation in the United States prior to being placed on sale.166 Dr. Yinong 
Yang, the plant pathologist credited with the creation, used CRISPR to edit 
the common white button mushroom (Agaricus bisporus) so that it would 
resist browning.167 By editing the mushroom to knock out one gene from the 
enzyme family that leads to browning, Dr. Yang successfully reduced the 
enzyme’s activity by 30%.168 In its evaluation, the USDA determined that 
since the edited mushroom did not contain any foreign genetic material, and 
did not represent “a plant pest or weed,” regulation by the agency was un-
necessary.169 
Furthermore, the USDA has also determined that other gene-edited 
plants (including corn, potatoes, and soybeans that have been edited using 
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TALENs instead of CRIPSR) do not require evaluation, according to exist-
ing regulations.170 This decision offers hope to companies and researchers 
pursuing gene-edited crops using CRISPR technology. However, the current 
regulations are under review and may change in the future. 
The review of CRISPR applications to plants is also being conducted 
abroad. Similar to the United States, countries such as Argentina have indi-
cated that genetically edited plants using CRISPR or TALENs are outside of 
the scope of existing GMO legislation.171 In Canada, products are evaluated 
according to the new “trait” introduced in the plant instead of the process by 
which the plant was developed.172 Moreover, the Canadian Food Inspection 
Agency (CFIA) must assess the environmental safety profile of plants com-
prising novel traits before the associated product can be released.173 The jury 
is still out in China, where authorities have not yet decided whether 
CRISPR-edited crops will be able to be planted.174 
But the biggest domino yet to fall is if the EU will ultimately decide to 
regulate CRISPR-edited plants. As discussed previously, the EU has some 
of the strictest regulations in the world with respect to GMO crops. Howev-
er, given the differences in CRISPR technology with older methods for ge-
netically modifying plants, the EU may follow the lead of the USDA and 
determine that CRISPR editing falls outside of the scope of current GMO 
regulations. 
A promising development for proponents of CRISPR in the EU came 
in late 2015, when the Swedish Board of Agriculture determined that some 
plants edited using CRISPR technology did not fall under the rigorous EU 
definition of a GMO.175 The Board issued its decision following an inquiry 
from researchers in Umeå and Uppsala in Sweden, and rendered an opinion 
that although some Arabidopsis plants modified using CRISPR fall within 
the scope of the EU’s GMO definition, other plants do not.176 
Following the decision in Sweden, the EU has not issued a definitive 
ruling regarding CRISPR editing in plants. Although the battle is far from 
over, the opening salvo by at least one country’s board of agriculture has 
offered hope for scientists and researchers that plant improvements achieved 
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by CRISPR may be easier to bring to market in Europe than their GMO 
counterparts. 
E. Recommendations on Future Regulation of CRISPR-Edited Products 
As technological advancement continues to carry on, the regulation of 
new scientific breakthroughs in the medical and agricultural industries is an 
important consideration. Although regulators and policy makers may be 
tempted to simply try and include CRISPR and other gene editing platforms 
into the existing framework of GMO regulations, the opinion of this author 
is that the CRISPR revolution provides a unique opportunity to redefine 
regulation of such groundbreaking products. 
Regardless of whether current GMO regulations are product or process 
focused, the same concerns underlie the regulatory context. For instance, the 
safety and efficacy of the genetically modified product must be considered, 
both for the organism being modified and for the consumer that will utilize 
the product. In addition, environmental concerns must also be addressed to 
ensure that the natural world will not be untowardly affected by the genetic 
modification. Regulatory review of a GMO product is a complex undertak-
ing that must balance the interest of the public, the affected organism, and 
the environment. 
However, the difficulty in performing this balancing act is considerably 
lessened when considering an organism that undergoes gene editing with 
CRISPR. The CRISPR system is simple and inexpensive for researchers to 
utilize.177 Furthermore, CRISPR modifications have the potential to improve 
the health and well-being of the consumer.178 In the human and the animal 
fields, genetic editing via CRISPR is being developed to treat and even cure 
diseases.179 In addition, in the field of agricultural biotechnology, modifica-
tion of livestock and crops using CRISPR is one possible solution to address 
the problem of feeding an ever-increasing world population.180 
Perhaps most importantly, the negative stigma sometimes associated 
with genetically modified organisms may be eased if an explanation of the 
genetic editing process is properly communicated to the general public. 
Many people’s perception of GMOs can be summarized in one term: 
“Frankenfish.”181 Critics view genetically modified organisms as a grotesque 
laboratory creation that represent an unnatural cobbling together of unrelat-
ed organisms to create a monstrous mutant, even when such GMOs have 
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undergone years of careful regulatory review and approval. This perception 
is difficult for many detractors to overcome, especially when the genome of 
one particular organism is in fact modified using genetic material from a 
second organism. 
However, gene editing using CRISPR alleviates these concerns. The 
CRISPR system does not insert nonnative genes into an organism’s genome 
– it simply corrects that organism’s defective or non-functioning gene and 
restores it to a proper, functioning state. In other words, following the 
CRISPR system, the end product is comprised solely of its own genetic ma-
terial.182 Thus, the impression of an outrageous “Frankenfish” being thrust 
upon the public should be eliminated if the public fully understands 
CRISPR’s precise and targeted gene editing techniques. 
In crafting new regulations for CRISPR-edited organisms, policy mak-
ers should pay careful attention to the fact that the gene editing procedure 
simply corrects defective genetic material in an organism, or replaces the 
defective genetic material with functioning genes from the organism’s own 
genome. The end product is typically indistinguishable from naturally oc-
curring organisms that have not undergone a gene editing process. Moreo-
ver, CRISPR can improve not only the end user but also the welfare of the 
edited organism itself, as observed by the previously described animal ap-
plications.183 
The FDA and USDA, as well as corresponding regulatory agencies 
worldwide, can learn from their previous experiences in regulating GMOs to 
guide regulation of CRISPR technology. First, with the rapid speed that 
CRISPR is developing, the agencies should announce a framework for re-
view sooner rather than later. Second, the agencies should ensure that they 
gather information from all interested parties in crafting new rules for regu-
lation. Concerns from both CRISPR advocates and CRISPR opponents 
should be expressed and considered in the rulemaking process. Finally, the 
agencies should articulate clear standards for the regulatory approach, in-
cluding a comparison of the CRISPR process with previously used genetic 
modification procedures. Given the benefits in using CRISPR gene editing 
compared to older methods, it would be beneficial if agencies address the 
regulations in the context of scientific progress instead of simply maintain-
ing the status quo for a possibly outdated GMO approval process. 
VI. CONCLUSION 
CRISPR technology is moving at a breakneck pace. Although regulato-
ry concerns are certainly valid, the benefits offered by the new technology 
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are also significant for the medical and agricultural world. Thus, it will be 
imperative for researchers and regulators to find common ground so that 
these valuable innovations can be brought to market for the benefit of man-
kind. 
